Agenus Inc (AGEN)

$3.44 +0.18 (5.52%)
Market Cap 125.18M
Revenue (ttm) 114.20M
Net Income (ttm) 120,000.00
EPS (ttm) N/A
PE Ratio 8.13
Forward PE 1.82
Profit Margin 0.11%
Debt to Equity Ratio -0.16
Volume 799,400
Avg Vol 883,240
Day's Range N/A - N/A
Shares Out 38.40M
Stochastic %K 22%
Beta 1.60
Analysts Strong Sell
Price Target $12.33

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGE...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 674 4400
Fax: 781 674 4200
Address:
3 Forbes Road, Lexington, United States
Biotechguy21
Biotechguy21 May. 13 at 11:11 AM
$AGEN this is so funny. and you are the fool who bought more of this pos recently 😂😂🤡🤡
1 · Reply
joechuck71
joechuck71 May. 13 at 10:08 AM
$AGEN Updated Gov This study has 20 locations Bot Bal CA
0 · Reply
BlackW1d0w
BlackW1d0w May. 13 at 2:22 AM
$AGEN its not even funny anymore. thats the sad part. its just sad
0 · Reply
A_I_R_IKAZEE
A_I_R_IKAZEE May. 13 at 2:12 AM
$AGEN @joechuck71
0 · Reply
BakerBrother
BakerBrother May. 12 at 11:59 PM
$AGEN Goldberg appears to have left and also the medical affair person who was sick oops interviewing for another job on the last stakeholder update.
1 · Reply
Biotechguy21
Biotechguy21 May. 12 at 11:57 PM
$AGEN what’s worse than a failing pos team? an arrogant pos team 😂😂🤡🤡💰💰🙏🙏
0 · Reply
manny11419
manny11419 May. 12 at 11:50 PM
$AGEN Is Richard Goldberg still with the company ?.
0 · Reply
joechuck71
joechuck71 May. 12 at 11:34 PM
$AGEN Ubs Group Ag 3/31/2026 234,439 add 115,621 97.309% $764
0 · Reply
joechuck71
joechuck71 May. 12 at 11:32 PM
$AGEN Vanguard still with us ! New Vanguard Capital Management Llc 3/31/2026 1,440,232 1,440,232 $4,695 New Vanguard Portfolio Management Llc 3/31/2026 1,195,109 1,195,109 $3,896 New Vanguard Fiduciary Trust Co 3/31/2026 200,498 200,498 $654
0 · Reply
Biotechguy21
Biotechguy21 May. 12 at 10:44 PM
$AGEN $INKT two of the biggest pos stocks out there.
0 · Reply
Latest News on AGEN
Agenus reports Q1 revenue $33.7M vs. $24.1M last year

2026-05-11T14:42:15.000Z - 1 day ago

Agenus reports Q1 revenue $33.7M vs. $24.1M last year

Agenus provides 2026 strategic priorities

2026-05-11T14:38:34.000Z - 1 day ago

Agenus provides 2026 strategic priorities

Agenus announces conclusion of SEC investigation with no enforcement action

2026-05-11T14:36:03.000Z - 1 day ago

Agenus announces conclusion of SEC investigation with no enforcement action

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

May 11, 2026, 8:45 AM EDT - 1 day ago

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

May 4, 2026, 4:30 PM EDT - 8 days ago

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

Apr 21, 2026, 10:00 AM EDT - 21 days ago

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

Agenus appoints BAP Pharma as global partner for BOT+BAL access programs

2026-04-21T13:51:54.000Z - 21 days ago

Agenus appoints BAP Pharma as global partner for BOT+BAL access programs

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

Apr 21, 2026, 8:00 AM EDT - 22 days ago

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

Agenus reports Phase 2 results from BOT and BAL with agenT-797

2026-04-17T20:51:02.000Z - 25 days ago

Agenus reports Phase 2 results from BOT and BAL with agenT-797

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

Apr 17, 2026, 4:43 PM EDT - 25 days ago

Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

Apr 3, 2026, 7:30 AM EDT - 5 weeks ago

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

Agenus announces first patient enrolled in Phase 3 BATTMAN trial of BOT+BAL

2026-04-01T11:48:30.000Z - 6 weeks ago

Agenus announces first patient enrolled in Phase 3 BATTMAN trial of BOT+BAL

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

Apr 1, 2026, 7:30 AM EDT - 6 weeks ago

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

Agenus Transcript: AGM 2026

Mar 31, 2026, 4:30 PM EDT - 6 weeks ago

Agenus Transcript: AGM 2026

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

Mar 26, 2026, 4:52 PM EDT - 6 weeks ago

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

Mar 17, 2026, 4:40 PM EDT - 2 months ago

Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

Options Volatility and Implied Earnings Moves Today, March 16, 2026

2026-03-16T12:05:11.000Z - 2 months ago

Options Volatility and Implied Earnings Moves Today, March 16, 2026

ASRT BKKT CTMX DLTR MVST NIU OPTT

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

Mar 16, 2026, 7:30 AM EDT - 2 months ago

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

Agenus triggers first $20M contingent payment under Zydus Lifesciences pact

2026-03-10T11:40:12.000Z - 2 months ago

Agenus triggers first $20M contingent payment under Zydus Lifesciences pact

Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

Mar 10, 2026, 7:30 AM EDT - 2 months ago

Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

Mar 4, 2026, 4:30 PM EST - 2 months ago

Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL

Feb 19, 2026, 3:15 PM EST - 2 months ago

Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL

Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

Feb 9, 2026, 1:00 PM EST - 3 months ago

Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

Agenus Transcript: Status update

Jan 28, 2026, 4:00 PM EST - 3 months ago

Agenus Transcript: Status update

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab

Jan 21, 2026, 7:30 AM EST - 3 months ago

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab

Agenus to Host First 2026 Stakeholder Webcast

Jan 20, 2026, 6:24 PM EST - 4 months ago

Agenus to Host First 2026 Stakeholder Webcast

Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.

Jan 15, 2026, 8:30 AM EST - 4 months ago

Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

Jan 15, 2026, 7:01 AM EST - 4 months ago

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

Jan 12, 2026, 7:30 AM EST - 4 months ago

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

Agenus files to sell 1.32M shares of common stock or holders

2025-12-29T22:10:27.000Z - 4 months ago

Agenus files to sell 1.32M shares of common stock or holders

Agenus publishes C-800-01 trial data in The Journal for ImmunoTherapy of Cancer

2025-12-23T13:20:36.000Z - 5 months ago

Agenus publishes C-800-01 trial data in The Journal for ImmunoTherapy of Cancer

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

Dec 23, 2025, 8:05 AM EST - 5 months ago

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

Nov 19, 2025, 4:01 PM EST - 6 months ago

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

Agenus appoints Jose Iglesias as chief medical affairs officer

2025-11-18T14:36:16.000Z - 6 months ago

Agenus appoints Jose Iglesias as chief medical affairs officer

Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

Nov 18, 2025, 8:41 AM EST - 6 months ago

Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

Agenus reports Q3 EPS $1.94, consensus $2.20

2025-11-10T13:05:24.000Z - 6 months ago

Agenus reports Q3 EPS $1.94, consensus $2.20

Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

Nov 10, 2025, 7:30 AM EST - 6 months ago

Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

Nov 5, 2025, 1:47 PM EST - 6 months ago

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

Agenus Transcript: Status Update

Oct 21, 2025, 4:00 PM EDT - 7 months ago

Agenus Transcript: Status Update

Agenus announces new data from its BOT/BAL at ESMO 2025

2025-10-17T12:10:28.000Z - 7 months ago

Agenus announces new data from its BOT/BAL at ESMO 2025

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Oct 17, 2025, 8:00 AM EDT - 7 months ago

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

Oct 16, 2025, 7:48 AM EDT - 7 months ago

Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

Agenus Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 10:00 AM EDT - 8 months ago

Agenus Transcript: H.C. Wainwright 27th Annual Global Investment Conference

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Sep 9, 2025, 7:43 AM EDT - 8 months ago

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 8:52 AM EDT - 8 months ago

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Agenus Transcript: Stakeholder Briefing

Aug 27, 2025, 4:00 PM EDT - 9 months ago

Agenus Transcript: Stakeholder Briefing

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Aug 26, 2025, 9:37 AM EDT - 9 months ago

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Aug 19, 2025, 7:30 AM EDT - 9 months ago

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Agenus Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 9 months ago

Agenus Earnings Call Transcript: Q2 2025

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Aug 11, 2025, 7:30 AM EDT - 9 months ago

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

Jul 31, 2025, 7:30 AM EDT - 10 months ago

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

Jul 25, 2025, 12:46 PM EDT - 10 months ago

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Jul 7, 2025, 8:55 AM EDT - 11 months ago

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Agenus, Noetik announce research collaboration to develop predictive biomarkers

2025-06-17T11:40:18.000Z - 11 months ago

Agenus, Noetik announce research collaboration to develop predictive biomarkers

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Jun 17, 2025, 7:30 AM EDT - 11 months ago

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Agenus Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:30 PM EDT - 1 year ago

Agenus Announces Virtual Annual Shareholders Meeting

Agenus price target raised to $6 from $4 at Baird

2025-06-04T11:30:22.000Z - 1 year ago

Agenus price target raised to $6 from $4 at Baird

Agenus upgraded to Buy from Neutral at H.C. Wainwright

2025-06-04T10:10:31.000Z - 1 year ago

Agenus upgraded to Buy from Neutral at H.C. Wainwright

Agenus Transcript: Collaboration

Jun 3, 2025, 4:30 PM EDT - 1 year ago

Agenus Transcript: Collaboration

Agenus selling U.S. manufacturing facilities to Zydus

2025-06-03T12:16:17.000Z - 1 year ago

Agenus selling U.S. manufacturing facilities to Zydus

Agenus, Zydus enter $141M collaboration for BOT/BAL production orders

2025-06-03T11:21:12.000Z - 1 year ago

Agenus, Zydus enter $141M collaboration for BOT/BAL production orders

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

May 30, 2025, 7:30 AM EDT - 1 year ago

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 15, 2025, 10:40 AM EDT - 1 year ago

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

Agenus Earnings Call Transcript: Q1 2025

May 12, 2025, 8:30 AM EDT - 1 year ago

Agenus Earnings Call Transcript: Q1 2025

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:30 AM EDT - 1 year ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

May 12, 2025, 7:20 AM EDT - 1 year ago

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Apr 28, 2025, 3:30 PM EDT - 1 year ago

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Apr 25, 2025, 1:05 PM EDT - 1 year ago

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Apr 23, 2025, 12:05 PM EDT - 1 year ago

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Mar 25, 2025, 4:40 PM EDT - 1 year ago

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Mar 19, 2025, 7:30 AM EDT - 1 year ago

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Agenus Earnings Call Transcript: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Agenus Earnings Call Transcript: Q4 2024

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Feb 26, 2025, 4:48 PM EST - 1 year ago

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Feb 25, 2025, 2:30 PM EST - 1 year ago

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Biotechguy21
Biotechguy21 May. 13 at 11:11 AM
$AGEN this is so funny. and you are the fool who bought more of this pos recently 😂😂🤡🤡
1 · Reply
joechuck71
joechuck71 May. 13 at 10:08 AM
$AGEN Updated Gov This study has 20 locations Bot Bal CA
0 · Reply
BlackW1d0w
BlackW1d0w May. 13 at 2:22 AM
$AGEN its not even funny anymore. thats the sad part. its just sad
0 · Reply
A_I_R_IKAZEE
A_I_R_IKAZEE May. 13 at 2:12 AM
$AGEN @joechuck71
0 · Reply
BakerBrother
BakerBrother May. 12 at 11:59 PM
$AGEN Goldberg appears to have left and also the medical affair person who was sick oops interviewing for another job on the last stakeholder update.
1 · Reply
Biotechguy21
Biotechguy21 May. 12 at 11:57 PM
$AGEN what’s worse than a failing pos team? an arrogant pos team 😂😂🤡🤡💰💰🙏🙏
0 · Reply
manny11419
manny11419 May. 12 at 11:50 PM
$AGEN Is Richard Goldberg still with the company ?.
0 · Reply
joechuck71
joechuck71 May. 12 at 11:34 PM
$AGEN Ubs Group Ag 3/31/2026 234,439 add 115,621 97.309% $764
0 · Reply
joechuck71
joechuck71 May. 12 at 11:32 PM
$AGEN Vanguard still with us ! New Vanguard Capital Management Llc 3/31/2026 1,440,232 1,440,232 $4,695 New Vanguard Portfolio Management Llc 3/31/2026 1,195,109 1,195,109 $3,896 New Vanguard Fiduciary Trust Co 3/31/2026 200,498 200,498 $654
0 · Reply
Biotechguy21
Biotechguy21 May. 12 at 10:44 PM
$AGEN $INKT two of the biggest pos stocks out there.
0 · Reply
Biotechguy21
Biotechguy21 May. 12 at 10:44 PM
$AGEN noted. 🤡🤡😂😂
0 · Reply
robbiekuss1
robbiekuss1 May. 12 at 8:23 PM
$AGEN @Diesel01 @Biotechguy21 @Brianrudi Little Dead Cat Bounce today right BrainTrust.
3 · Reply
BlackW1d0w
BlackW1d0w May. 12 at 8:23 PM
$AGEN maybe the new fda head will like Garo .. who knows 🤣
0 · Reply
2_logs_higher
2_logs_higher May. 12 at 2:04 PM
$AGEN & $INKT
0 · Reply
jlemx
jlemx May. 12 at 1:39 PM
$AGEN Garo is right: when an innovative drug is safe and effective, after being tested on as many as 1,200 patients, it must be approved ! At least provisionally or conditionally, no question about it! Only old, obtuse people at the FDA. Patients can't wait years for something that is known to work.
3 · Reply
neversurrender2024
neversurrender2024 May. 12 at 1:14 PM
$AGEN best case scenaio.. 1 billion dollar market cap 1 billion shares outstanding.....institutiional investors are done with the greedy delussional man running the show...there will be no aa , any approval is years away and all the clown has left is his atm...phase 2 numbers obviously to make the cut and the europe hype will not help much in the way of funding .......its going lower folks......
0 · Reply
A_I_R_IKAZEE
A_I_R_IKAZEE May. 12 at 12:59 PM
$AGEN good morning to everyone except that cocksuckin ceo
0 · Reply
Biotechguy21
Biotechguy21 May. 12 at 12:33 PM
$AGEN do you ever ask yourself how I am so much smarter than you all? how did I know this was a pos stock? 😂😂💰💰🙏🙏👀👀
1 · Reply
Biotechguy21
Biotechguy21 May. 12 at 12:10 PM
$AGEN your math will cost you every penny you invest here. 😂😂😂😂
0 · Reply
Gbtx1212
Gbtx1212 May. 12 at 10:50 AM
$AGEN Nothing has changed with my investment thesis here. - Garo is still a greedy SOB (known for years), and his gifting to himself of over a million shares is an atrocious abuse of shareholders. But this is what I expect of him. - Even with the Zydus deal, the company will need more cash to finish the P3 trial. While I wish he would use a partnership to get funds and FDA leverage, anyone who has followed this company for the last few years knows that’s not going to happen. So the ATM use when the SP spiked to 5 is not surprising. - I don’t think he will have OS data from the P2. If he has it, he would be screaming it from the mountaintops. - I was hoping for more French revenue. That was the one surprise to the downside. - The most important thing is that the P3 is enrolling. If they had said they are struggling to enroll the P3, or it was slower than expected, I would be concerned. If another CTLA-4 received approval in an earlier line of CRC, I would be concerned.
8 · Reply
Biotechguy21
Biotechguy21 May. 12 at 10:49 AM
$AGEN good luck with no money left
0 · Reply
manny11419
manny11419 May. 12 at 10:22 AM
$AGEN A major catalyst this year that may portents AA is the three years survival numbers. If Garo's correct the rate of progression should slow, we already know that the maturing data in Crc is getting better, as per Garo. As was explained in the last CC, the FDA did not reject the application, they merely advise the Co. that current Data may not support AA, it seems the company may force the FDA's hands by officially file an AA application, which another company done successfully.
0 · Reply